Table 2.
Clinicopathological features and basic characteristics according to used agents.
| Variables | Placebo | Royal Jelly | p Value |
|---|---|---|---|
| Sunitinib | n = 11 | n =10 | |
| Age (mean ± SD), years | 66.5 ± 8.3 | 67.8 ± 5.8 | 0.673 |
| Gender; Male/Female, n (%) | 6/5 (45.5) | 8/2 (20.0) | 0.217 |
| Performance Status; 0/1 | 7/4 (36.4) | 6/4 (40.0) | 0.864 |
| Pathological Type; Conventional | 11 (100.0) | 8 (80.0) | 0.297 |
| Fuhrman grade; 2/3+4 | 1/10 (90.9) | 2/8 (80.0) | 0.476 |
| pT stage; 1+2/3+4 | 2/9 (81.8) | 3/7 (70.0) | 0.525 |
| Lymph Node Metastasis; Presence | 7 (63.6) | 6 (60.0) | 0.864 |
| Distant Metastasis; Presence | 9 (81.8) | 8 (80.0) | 0.916 |
| Neo-Adjuvant Setting; Yes | 1 (9.1) | 0 (0.0) | 0.329 |
| Past Therapy Used TKI; Presence | 1 (9.1) | 0 (0.0) | 0.329 |
| Others | n = 6 | n = 6 | |
| Age (mean ± SD); years | 64.5 ± 3.8 | 72.5 ± 5.3 | 0.013 |
| Gender; Male / Female | 6/0 (0.0) | 3/3 (50.0) | 0.182 |
| Performance Status; 0/1 | 2/4 (66.7) | 1/5 (83.3) | 0.505 |
| Pathological Type; Conventional | 5 (83.3) | 5 (83.3) | 0.999 |
| Fuhrman grade; 2/3+4 | 1/5 (83.3) | 3/3 (50.0) | 0.221 |
| pT Stage; 1+2/3+4 | 1/5 (83.3) | 2/4 (66.7) | 0.501 |
| LN Metastasis; Presence | 3 (50.0) | 3 (50.0) | 0.999 |
| Distant Metastasis; Presence | 6 (100.0) | 4 (66.7) | 0.121 |
| Neo-Adjuvant Setting; Yes | 0 (0.0) | 1 (16.7) | 0.296 |
| Past Therapy Used TKI; Presence | 1 (16.7) | 2 (33.3) | 0.505 |